Master Protocol to Assess the Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2024-02-12

Target enrollment:

Participant gender:

This trial will evaluate the safety and efficacy of first time in human engineered T-cell therapies, in participants with advanced tumors.

Phase 1

GlaxoSmithKline

Cyclophosphamide
Fludarabine